Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Arena is a wholly owned subsidiary of Pfizer
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with moderately to severely active ulcerative colitis (UC) are eligible to enroll into this study if they fulfill all of the following:
Must have completed the Week 12 visit of Study APD334-302
Ability to provide written informed consent or assent (parent or legal guardian must provide consent for a participant \< 20 years of age or as required per local regulations who has assented to participate in the study) and to be compliant with the schedule of protocol assessments. Enrollment of participants \< 20 years should be conducted only if acceptable according to local laws and regulations.
Both men and women subjects agree to use a highly effective method of birth control if the possibility of conception exists
You may not be if
If the Investigator considers the participant to be unsuitable for any reason to participate in the study
Participants requiring partial or total colectomy during the APD334-302 study
Participants requiring treatment with prohibited concomitant medications
Clareo Health | Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
